The liquid biopsy solutions separate cancer cells from a small amount of blood sample. The clinical studies serve to validate the clinical utility of CTCs as a biomarker in late stage lung cancer.
SINGAPORE (Sept 9): Biolidics, the medical technology company, is collaborating with Hangzhou Normal University to undertake clinical investigations to validate the clinical utility of CTCs as a biomarker in late stage lung cancer.
In addition, the group’s liquid biopsy solutions will be used as a companion diagnostics test to validate a combination treatment for lung cancer.
